# The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes

> **NIH NIH K01** · JOHNS HOPKINS UNIVERSITY · 2022 · $150,982

## Abstract

PROJECT SUMMARY/ABSTRACT
Jung-Im Shin, MD, PhD, is an Assistant Scientist in the Department of Epidemiology at the Johns Hopkins
Bloomberg School of Public Health. She seeks a K01 Mentored Research Scientist Development Award in
order to obtain essential skills and mentored research experience for an independent career as a research
scientist in the field of pharmacoepidemiology and diabetes. The research proposal details a five-year plan
consisting of in-depth training in novel causal inference methods, mentorship by Dr. Morgan Grams, MD,
PhD, and Dr. Elizabeth Selvin, PhD, MPH, and pharmacoepidemiologic research in utilization, effectiveness,
and safety of second-line therapy in patients with type 2 diabetes. The specific aims of the research agenda
are to: 1) Describe the real-world epidemiology of second-line therapy among people with diabetes after
metformin monotherapy; 2) Evaluate real-world effectiveness of 5 classes of second-line therapy for
hyperglycemia management among similar people with diabetes after metformin monotherapy; and 3)
Evaluate real-world risks of adverse events and benefits on long-term clinical outcomes of 5 classes of second-
line therapy among similar people with diabetes after metformin monotherapy. Immediate career goals include
the mastery of applying target trial emulation and estimating the effect of a dynamic treatment regime with
Robin’s g-methods through an academic curriculum integrated with the research plan. Long-term, Dr. Shin
aims to lead independent research programs investigating optimal treatment and decision-making to improve
health outcomes of patients with type 2 diabetes. Completion of the proposed aims will provide vital information
relevant to the approximately thirty million U.S. patients with type 2 diabetes. Type 2 diabetes is associated
with high levels of morbidity and mortality. Although consensus exists around first-line therapy, there remains
great uncertainty regarding the optimal choice of a second-line therapy, with inconsistent recommendations
across guidelines. A better understanding of the risks and benefits of different classes of second-line
antidiabetic drugs would greatly help clinical practice in patients with type 2 diabetes.

## Key facts

- **NIH application ID:** 10427202
- **Project number:** 5K01DK121825-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Jung-Im Shin
- **Activity code:** K01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $150,982
- **Award type:** 5
- **Project period:** 2019-07-01 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10427202

## Citation

> US National Institutes of Health, RePORTER application 10427202, The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes (5K01DK121825-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10427202. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*